查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951297

基因組編輯市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、交付模式、應用、模式、最終用戶、地區和競爭格局分類，2021-2031年）

Genome Editing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Technology, By Deliver Mode, By Application, By Mode, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因組編輯市場預計將經歷顯著成長，從 2025 年的 93.9 億美元成長到 2031 年的 236.6 億美元，複合年成長率為 16.65%。

基因組編輯是指透過在特定位點添加、移除或修改遺傳物質來改變生物體DNA的一系列技術。推動這一領域快速發展的關鍵因素包括全球癌症和遺傳疾病發病率的不斷上升，以及生物技術研究領域的大量資本投入。這一發展動能也體現在近期的產業成就中。根據再生醫學聯盟預測，細胞和基因治療領域預計在2024年獲得創紀錄的九項全球監管核准，這將證實這些先進治療方法的臨床療效，並提振投資者信心。

市場概覽
預測期 2027-2031
市場規模：2025年 93.9億美元
市場規模：2031年 236.6億美元
複合年成長率：2026-2031年 16.65%
成長最快的細分市場 CRISPR
最大的市場 北美洲

儘管取得了這些進展，但市場在安全性和倫理方面仍面臨著許多挑戰。脫靶效應（導致非預期基因改變）的潛在風險是一大技術障礙，也使監管流程複雜化。因此，製造商必須遵守嚴格的合規標準，並應對漫長的研發週期。這些障礙增加了營運負擔，並可能減緩新型基因編輯產品進入商業市場和廣泛應用的速度。

市場促進因素

公共和私人對基因組研究的投入不斷增加，正在推動市場發展，成為將基因編輯理論概念轉化為實際臨床治療的重要催化劑。這筆資金的湧入使生技公司能夠支持下一代體內療法所需的高投入研發。例如，大規模創業投資資金籌措已展現出新型工程平台和標靶遞送系統的潛力。如同2024年3月新聞稿「Capstan Therapeutics宣布完成1.75億美元B輪資金籌措」所述，Capstan Therapeutics籌集了1.75億美元，用於推進其用於治療自體免疫疾病的體內嵌合體抗原受體T細胞（CAR-T）候選藥物的研發。此類投資顯示市場對解決商業性化規模化生產的關鍵遞送難題充滿信心。

同時，CRISPR 和下一代技術的快速發展正將治療標靶從遺傳性癌症擴展到更廣泛的適應症。研發人員正在利用精準的鹼基編輯技術和新型酵素來治療複雜疾病，同時最大限度地降低脫靶風險。這種技術革新在臨床研發管線的多元化中顯而易見；根據美國基因與細胞治療學會 (ASGCT) 於 2024 年 10 月發布的《2024 年第三季基因、細胞和 RNA 治療趨勢報告》，51% 的新基因治療臨床試驗針對的是非腫瘤領域。此外，主要市場參與者擁有雄厚的財力來支持創新，CRISPR Therapeutics 公司報告稱，其 2024 年的現金儲備約為 19 億美元。

市場挑戰

與脫靶效應相關的固有風險仍然是阻礙全球基因組編輯市場成長的一大安全障礙。由於非預期基因突變可能導致嚴重的長期健康問題，包括癌症，監管機構正在實施日益嚴格的合規標準。這些安全隱患要求進行廣泛的臨床前檢驗和長期的病患監測，從而顯著延長了研發週期。因此，企業面臨著不斷增加的營運成本和從研究到人體試驗的延誤，造成商業化過程中的瓶頸，並阻礙了快速進入市場。

監管放緩的趨勢也反映在近期的行業發展趨勢。根據美國基因與細胞治療學會（ASGCT）預測，2025年第三季度，研發速度有所放緩，全球僅啟動了125項新的臨床試驗。這項降幅凸顯了精準基因改造安全標準的複雜性如何限制了能夠進入臨床應用的新治療方法數量。這些技術和安全方面的障礙需要更謹慎和漫長的研發過程，從而有效地減緩了新產品上市的速度。

市場趨勢

將人工智慧 (AI) 融入精準設計正在從根本上改變基因組編輯領域。與依賴細菌資料庫探索的傳統方法不同，生成式 AI 模型正在創建具有更高特異性的合成編輯系統。這種計算方法透過在實驗室檢驗之前預測並最大限度地減少非預期編輯，直接解決了脫靶效應的挑戰。 Profluent 公司在 2024 年 4 月發布的題為「AI 驅動的人類基因組編輯」的新聞稿中宣布了一項突破性進展：該公司的 AI 生成的 OpenCRISPR-1 系統與標準 SpCas9 酶相比，將脫靶編輯減少了 95%，這充分展現了機器學習在提高治療安全性方面的巨大潛力。

同時，基因編輯作物正迅速走向商業化，其影響範圍也從人類治療擴展到全球糧食安全。農業生物技術開發商正利用CRISPR技術培育具有改良性狀和氣候變遷適應能力的作物，使其從實驗室走向零售市場。該領域的策略整合也在進行中，大型農業公司正與專業的基因編輯公司建立合作關係。例如，根據2024年9月題為「Pairwise與Corteva合作」的新聞稿，Pairwise獲得了Corteva 2,500萬美元的股權投資，用於加速開發永續農業解決方案，這表明業界對非治療應用領域充滿信心。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球基因組編輯市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（CRISPR/Cas9、TALENs/MegaTALs、ZFN、Meganucleases、其他）
    • 依遞送方式（體外、體內）
    • 依應用領域（基因工程、臨床應用）
    • 按模式（合約開發、內部開發）
    • 依最終用戶（生技/製藥公司、學術/政府研究機構、合約研究組織）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美基因組編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲基因組編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因組編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章 中東和非洲基因組編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲基因組編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球基因組編輯市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Cibus Inc
  • Recombinetics, Inc
  • Merck & Co., Inc
  • Sangamo Therapeutics Inc
  • Editas Medicine Inc
  • Precision BioSciences Inc
  • CRISPR Therapeutics Inc
  • Intellia Therapeutics, Inc
  • Caribou Biosciences, Inc
  • Takara Bio Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4542

The Global Genome Editing Market is projected to experience substantial growth, increasing from a valuation of USD 9.39 Billion in 2025 to USD 23.66 Billion by 2031, representing a CAGR of 16.65%. Genome editing involves a range of technologies that allow scientists to modify an organism's DNA by adding, removing, or altering genetic material at specific sites. The primary drivers behind this expansion include the growing prevalence of cancer and genetic disorders worldwide, coupled with significant capital investment in biotechnology research. This momentum is highlighted by recent industry achievements; according to the Alliance for Regenerative Medicine, the cell and gene therapy sector secured a record nine global regulatory approvals in 2024, confirming the clinical viability of these advanced therapies and boosting investor confidence.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 9.39 Billion
Market Size 2031USD 23.66 Billion
CAGR 2026-203116.65%
Fastest Growing SegmentCRISPR
Largest MarketNorth America

Despite these advancements, the market faces notable challenges related to safety and ethical concerns. The potential for off-target effects, where unintended genetic modifications occur, serves as a major technical barrier that complicates the regulatory process. Consequently, manufacturers must adhere to strict compliance standards and navigate extended development timelines. These hurdles increase operational burdens and may slow the pace at which new genome editing products enter the commercial market and achieve widespread adoption.

Market Driver

Rising public and private funding for genomic research serves as a major catalyst for the market, facilitating the translation of theoretical gene editing concepts into viable clinical therapies. This influx of capital enables biotechnology firms to support the capital-intensive research and development necessary for next-generation in vivo treatments. For example, large venture capital rounds are validating the potential of novel engineering platforms and targeted delivery systems. As noted in the 'Capstan Therapeutics Announces $175M Series B Financing' press release from March 2024, Capstan Therapeutics raised $175 million to advance its in vivo chimeric antigen receptor T cell candidate for autoimmune disorders. Such investments demonstrate strong market confidence in resolving the delivery challenges essential for commercial scalability.

Simultaneously, rapid advancements in CRISPR and next-generation technologies are broadening the therapeutic scope beyond hereditary cancers to cover a wider range of indications. Developers are utilizing precise base editing techniques and novel enzymes to treat complex conditions while minimizing off-target risks. This technological evolution is evident in the diversification of clinical pipelines; according to the American Society of Gene & Cell Therapy's 'Gene, Cell, + RNA Therapy Landscape Q3 2024 Report' published in October 2024, 51% of new gene therapy trials focused on non-oncology indications. Furthermore, leading market players maintain robust financial health to sustain innovation, with CRISPR Therapeutics reporting a cash position of approximately $1.9 billion in 2024.

Market Challenge

The inherent risk of off-target effects remains a significant safety barrier that restricts the growth of the global genome editing market. Since unintended genetic alterations can lead to severe long-term health issues, such as oncogenesis, regulatory bodies enforce increasingly rigorous compliance standards. These safety concerns necessitate extensive preclinical validation and prolonged patient monitoring, which significantly extends development timelines. Consequently, companies face escalating operational costs and delays in transitioning candidates from research to human testing, creating a bottleneck in the commercial pipeline that discourages rapid market entry.

This regulatory slowdown is reflected in recent industry activity. According to the American Society of Gene & Cell Therapy, the sector experienced a decline in development velocity during the third quarter of 2025, with only 125 new clinical trials initiated globally. This contraction highlights how the complexity of meeting safety thresholds for precise genetic modification limits the volume of new therapies advancing to clinical stages. By necessitating a more cautious and protracted development approach, these technical and safety hurdles effectively dampen the rate at which new products can reach the market.

Market Trends

The integration of artificial intelligence into precision design is fundamentally transforming the genome editing landscape. Moving beyond traditional methods that rely on mining bacterial databases, generative AI models are now creating synthetic editing systems with superior specificity. This computational approach directly tackles the challenge of off-target effects by predicting and minimizing unintended edits before laboratory validation. A significant breakthrough occurred when Profluent announced in their April 2024 press release, 'Editing the Human Genome with AI', that their AI-generated OpenCRISPR-1 system achieved a 95% reduction in off-target editing compared to the standard SpCas9 enzyme, demonstrating the potential of machine learning to enhance therapeutic safety.

Concurrently, the market is seeing the rapid commercialization of gene-edited agricultural crops, extending the industry's influence beyond human therapeutics to global food security. Agricultural biotechnology developers are applying CRISPR technologies to create crops that are resilient to climate change and offer improved traits, moving from experimental trials to retail markets. This sector is also experiencing strategic consolidation as major agricultural companies partner with specialized editing firms. For instance, according to a September 2024 press release titled 'Pairwise Partners with Corteva', Pairwise secured a $25 million equity investment from Corteva to accelerate the development of sustainable agricultural solutions, signaling strong industrial confidence in non-therapeutic applications.

Key Market Players

  • Cibus Inc
  • Recombinetics, Inc
  • Merck & Co., Inc
  • Sangamo Therapeutics Inc
  • Editas Medicine Inc
  • Precision BioSciences Inc
  • CRISPR Therapeutics Inc
  • Intellia Therapeutics, Inc
  • Caribou Biosciences, Inc
  • Takara Bio Inc

Report Scope

In this report, the Global Genome Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genome Editing Market, By Technology

  • (CRISPR)/Cas9
  • TALENs/MegaTALs
  • ZFN
  • Meganuclease
  • Others

Genome Editing Market, By Deliver Mode

  • Ex-vivo
  • In-vivo

Genome Editing Market, By Application

  • Genetic Engineering
  • Clinical Applications

Genome Editing Market, By Mode

  • Contract
  • In-house

Genome Editing Market, By End User

  • Biotechnology and pharmaceutical companies
  • Academic and government research institutes
  • Contract research organizations

Genome Editing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genome Editing Market.

Available Customizations:

Global Genome Editing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genome Editing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology ((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, Others)
    • 5.2.2. By Deliver Mode (Ex-vivo, In-vivo)
    • 5.2.3. By Application (Genetic Engineering, Clinical Applications)
    • 5.2.4. By Mode (Contract, In-house)
    • 5.2.5. By End User (Biotechnology and pharmaceutical companies, Academic and government research institutes, Contract research organizations)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Genome Editing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Deliver Mode
    • 6.2.3. By Application
    • 6.2.4. By Mode
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genome Editing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Deliver Mode
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Mode
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Genome Editing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Deliver Mode
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Mode
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Genome Editing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Deliver Mode
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Mode
        • 6.3.3.2.5. By End User

7. Europe Genome Editing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Deliver Mode
    • 7.2.3. By Application
    • 7.2.4. By Mode
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genome Editing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Deliver Mode
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Mode
        • 7.3.1.2.5. By End User
    • 7.3.2. France Genome Editing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Deliver Mode
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Mode
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Genome Editing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Deliver Mode
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Mode
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Genome Editing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Deliver Mode
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Mode
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Genome Editing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Deliver Mode
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Mode
        • 7.3.5.2.5. By End User

8. Asia Pacific Genome Editing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Deliver Mode
    • 8.2.3. By Application
    • 8.2.4. By Mode
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Genome Editing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Deliver Mode
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Mode
        • 8.3.1.2.5. By End User
    • 8.3.2. India Genome Editing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Deliver Mode
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Mode
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Genome Editing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Deliver Mode
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Mode
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Genome Editing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Deliver Mode
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Mode
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Genome Editing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Deliver Mode
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Mode
        • 8.3.5.2.5. By End User

9. Middle East & Africa Genome Editing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Deliver Mode
    • 9.2.3. By Application
    • 9.2.4. By Mode
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Genome Editing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Deliver Mode
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Mode
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Genome Editing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Deliver Mode
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Mode
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Genome Editing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Deliver Mode
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Mode
        • 9.3.3.2.5. By End User

10. South America Genome Editing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Deliver Mode
    • 10.2.3. By Application
    • 10.2.4. By Mode
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genome Editing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Deliver Mode
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Mode
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Genome Editing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Deliver Mode
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Mode
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Genome Editing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Deliver Mode
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Mode
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Genome Editing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cibus Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Recombinetics, Inc
  • 15.3. Merck & Co., Inc
  • 15.4. Sangamo Therapeutics Inc
  • 15.5. Editas Medicine Inc
  • 15.6. Precision BioSciences Inc
  • 15.7. CRISPR Therapeutics Inc
  • 15.8. Intellia Therapeutics, Inc
  • 15.9. Caribou Biosciences, Inc
  • 15.10. Takara Bio Inc

16. Strategic Recommendations

17. About Us & Disclaimer